Fosun Pharma (02196) increases investment in overseas layout of innovative drugs. Fosun Pharma Industry signed a "Cooperation and Option Agreement" with Clavis Bio.

Wisdom Finance APP News, Fosun Pharma (02196) announced that on December 18, 2025, its controlling subsidiary Fosun Pharmaceutical Industry and its partner Clavis Bio signed a "Cooperation and Option Agreement". According to the agreement, during the agreed cooperation period, Fosun Pharmaceutical Industry and Clavis Bio will jointly select targets (based on Clavis Bio's nomination) and drive preclinical development of compounds targeting the selected target (i.e. the collaboration project). Clavis Bio has the exclusive option to develop, produce and commercialize the collaboration project globally outside of China, Hong Kong and Macao; regardless of whether the partner exercises the above option, the group has the exclusive rights to develop, produce and commercialize the collaboration project in China, Hong Kong, and Macao.